PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.59M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.31%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-6.07%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-8.06%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-9.04%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-1.78%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
No Data
No Data available this quarter, please select a different quarter.
-0.79%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-1.47%
Share reduction while ADI is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.44%
Reduced diluted shares while ADI is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-0.16%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
-48.39%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-53.02%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
133.94%
10Y revenue/share CAGR at 75-90% of ADI's 155.39%. Bill Ackman would press for new markets or product lines to narrow the gap.
38.70%
5Y revenue/share CAGR under 50% of ADI's 107.77%. Michael Burry would suspect a significant competitive gap or product weakness.
28.08%
3Y revenue/share CAGR under 50% of ADI's 69.04%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
498.85%
10Y OCF/share CAGR 1.25-1.5x ADI's 390.08%. Bruce Berkowitz would confirm if the firm's long-term capital allocation yields better cash returns.
175.85%
5Y OCF/share CAGR above 1.5x ADI's 99.96%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
116.94%
3Y OCF/share CAGR above 1.5x ADI's 42.81%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
9620.45%
Net income/share CAGR above 1.5x ADI's 1023.77% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
187.69%
5Y net income/share CAGR above 1.5x ADI's 97.06%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
83.48%
3Y net income/share CAGR similar to ADI's 82.13%. Walter Schloss would attribute it to shared growth factors or demand patterns.
25.60%
Below 50% of ADI's 280.91%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
-7.65%
Negative 5Y equity/share growth while ADI is at 104.62%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-6.64%
Negative 3Y equity/share growth while ADI is at 95.75%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
597.21%
10Y dividend/share CAGR above 1.5x ADI's 141.00%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
156.46%
5Y dividend/share CAGR above 1.5x ADI's 41.97%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
102.64%
3Y dividend/share CAGR above 1.5x ADI's 20.32%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
19.30%
AR growth well above ADI's 11.57%. Michael Burry fears inflated revenue or higher default risk in the near future.
-3.88%
Inventory is declining while ADI stands at 1.10%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
1.79%
Asset growth well under 50% of ADI's 6.74%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-3.87%
We have a declining book value while ADI shows 5.43%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
21.41%
We have some new debt while ADI reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
-2.75%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
No Data
No Data available this quarter, please select a different quarter.